The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of
childbearing age, which is usually characterized by hormonal imbalance and metabolism
problems such as hyperandrogenism and obesity. Diane 35 pills are classified as oral
contraceptives, which effectively reduces circulating androgens and are treatment for
hyperandrogenism caused androgenic skin symptoms and irregular menstrual cycles. GLP-1
Receptor Agonist(e.g. exenatide, liraglutide) have the effects of lowering blood sugar and
weight control by inhibiting of gastric emptying and reducing food intake. This study aims to
evaluate the effect of metformin-GLP-1 Receptor agonist combination versus metformin-Diane-35
combination treatment on lipid metabolism and cardiovascular risks in overweight polycystic
ovarian syndrome (PCOS) patients.
Phase:
Phase 4
Details
Lead Sponsor:
Xinqiao Hospital of Chongqing
Collaborators:
Azienda Ospedaliera Universitaria Policlinico "G. Martino" University of Messina